| Literature DB >> 30829483 |
Zhen Chen1,2, Wakana Mori3, Xiaoyun Deng1, Ran Cheng1, Daisuke Ogasawara4, Genwei Zhang5, Michael A Schafroth4, Kenneth Dahl1, Hualong Fu1, Akiko Hatori3, Tuo Shao1, Yiding Zhang3, Tomoteru Yamasaki3, Xiaofei Zhang1, Jian Rong1, Qingzhen Yu1, Kuan Hu3, Masayuki Fujinaga3, Lin Xie3, Katsushi Kumata3, Yuancheng Gou6, Jingjin Chen6, Shuyin Gu6, Liang Bao6, Lu Wang1, Thomas Lee Collier1, Neil Vasdev1, Yihan Shao5, Jun-An Ma2, Benjamin F Cravatt4, Christopher Fowler7, Lee Josephson1, Ming-Rong Zhang3, Steven H Liang1.
Abstract
Monoacylglycerol lipase (MAGL) is a serine hydrolase that degrades 2-arachidonoylglycerol (2-AG) in the endocannabinoid system (eCB). Selective inhibition of MAGL has emerged as a potential therapeutic approach for the treatment of diverse pathological conditions, including chronic pain, inflammation, cancer, and neurodegeneration. Herein, we disclose a novel array of reversible and irreversible MAGL inhibitors by means of "tail switching" on a piperazinyl azetidine scaffold. We developed a lead irreversible-binding MAGL inhibitor 8 and reversible-binding compounds 17 and 37, which are amenable for radiolabeling with 11C or 18F. [11C]8 ([11C]MAGL-2-11) exhibited high brain uptake and excellent binding specificity in the brain toward MAGL. Reversible radioligands [11C]17 ([11C]PAD) and [18F]37 ([18F]MAGL-4-11) also demonstrated excellent in vivo binding specificity toward MAGL in peripheral organs. This work may pave the way for the development of MAGL-targeted positron emission tomography tracers with tunability in reversible and irreversible binding mechanisms.Entities:
Year: 2019 PMID: 30829483 PMCID: PMC6581563 DOI: 10.1021/acs.jmedchem.8b01778
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446